Back to Faculty
Co-Chair

Kathleen Moore

MD, MS
Deputy Director and Director of Phase 1
Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center

Kathleen Moore is a Professor in the Section of Gynecologic Oncology, Deputy Director and Director of the Phase I Program for the Buffett Cancer Center at the University of Nebraska Medical Center. She attended medical school at the University of Washington School of Medicine and completed her residency in obstetrics and gynecology at the University Health Center of Pittsburgh. Dr Moore completed a fellowship in gynecologic oncology at the University of Oklahoma Health Sciences Center while simultaneously earning a master's degree in epidemiology. She is board certified in obstetrics and gynecology as well as gynecologic oncology and hospice and palliative care. She has published over 400 peer-reviewed publications and has a clinical research interest in drug development and phase I-3 clinical trials.

2026 Sessions

General Session

Front-Line Maintenance Therapy for Ovarian Cancer: It is a PARPi and Bevacizumab World – Don’t Fix What Is Not Broken vs We Can Do Better Than HRD – Opportunities for New Biomarkers and Agents to Improve Outcomes

Presenters will examine the strength and limitations of current evidence supporting standard maintenance regimens alongside evolving data that may refine patient selection and...

  • Moderator
    • Kathleen Moore, MD, MS
  • Presenter
    • Debra Richardson, MD
    • Angeles Secord, MD, MHSc
Gynecological Cancers

It is a PARPi and Bevacizumab World – Don’t Fix What Is Not Broken

Presenters will examine the strength and limitations of current evidence supporting standard maintenance regimens alongside evolving data that may refine patient selection and improve outcomes in ovarian cancer. The discussion will address resistance, toxicity, and the future direction of personalized maintenance therapy. Faculty will provide expert insight into how these competing strategies may shape clinical practice.

Review the most recent clinical trial data supporting these strategies, including outcomes across biomarker-defined subgroups. Faculty will discuss optimal patient selection, sequencing considerations, and management of treatment-related toxicities, giving learners a clearer understanding of the role of established maintenance approaches in contemporary ovarian cancer care.

Presenter

Saturday, March 14 4:25–4:45 PM
Room Royal Ballroom 1
Gynecological Cancers

Debra Richardson

MD
Professor
Stephenson Cancer Center, University of Oklahoma Health Sciences Center

Debra L. Richardson is Professor of Obstetrics & Gynecology and the Division Director of Gynecologic Oncology at the Stephenson Cancer Center, University of Oklahoma Health Sciences Center. Dr. Richardson is a clinician, surgeon, and also a clinical trialist. She spends 50% of her time leading phase I clinical trials within the SCC early phase drug development unit. She was one of the inagural GOG Foundation Scholars, and a member of the GOG Partners Investigator Council. She is very involved in NRG Oncology, and is a member of the Ovarian and Developmental Therapeutics Committees and the Chair of the Early Phase Trial Oversight Committee. She completed residency at the University of Connecticut, Gynecologic Oncology fellowship at The Ohio State University, and was faculty at UT Southwestern for 8 years. Her research goals are to develop and lead science based and translationally driven early phase trials and move promising treatments into late phase trials. Dr. Richardson enjoys doing medical missions- and has completed one to Nigeria and one to the Phillipines. Her next one will be in Malawi.

We Can Do Better Than HRD – Opportunities for New Biomarkers and Agents to Improve Outcomes

Presenters will examine the strength and limitations of current evidence supporting standard maintenance regimens alongside evolving data that may refine patient selection and improve outcomes in ovarian cancer. The discussion will address resistance, toxicity, and the future direction of personalized maintenance therapy. Faculty will provide expert insight into how these competing strategies may shape clinical practice.

Explore emerging biomarkers and novel therapeutic agents shaping frontline maintenance strategies for ovarian cancer. Faculty will review evolving evidence on molecular and genomic markers that may better predict benefit and guide personalized maintenance therapy. The discussion will highlight investigational agents, mechanisms of resistance, and how these advances may complement or challenge current standards of care.

Presenter

Saturday, March 14 4:45–5:05 PM
Room Royal Ballroom 1
Gynecological Cancers

Angeles Secord

MD, MHSc
Professor
Duke Cancer Institute

Dr. Angeles Alvarez Secord, M.D., M.H.Sc., is a Professor in the Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, Duke University Heath System. She graduated AOA with Honors from the University of Washington School of Medicine in Seattle, Washington. Dr. Secord completed her residency in Obstetrics and Gynecology and her fellowship in Gynecologic Oncology at the Duke University Medical Center in Durham, North Carolina. Upon completing her fellowship in 2001, she joined the Division of Gynecologic Oncology at Duke. She is currently the Director of Gynecologic Oncology Clinical Trials, the Associate Director of Clinical Research, Gynecology Oncology, and one of the Principal Investigators for NRG Oncology at the Duke Cancer Institute. Dr. Secord has served as a board member for several professional organizations including Society of Gynecologic Oncology (SGO), GOG Foundation, and American Association of Gynecology and Obstetrics Foundation (AAOGF). She is passionate about mentoring the next generation of investigators and previously served as the AAOGF Scholar Committee Chair, and currently serves as the NRG Oncology Investigator Career Development Subcommittee co-Chair and the GOG Foundation Education and Mentoring Chair. Her life experience inspired her motto, “Empower through Teamwork", and fostering synergistic collaboration to help people with gynecologic cancers live longer and better lives.
General Session

Front-Line Metastatic Endometrial Cancer: Immunotherapy for All vs Molecular Profiling to Individualize Therapy – Immunotherapy Should Not Be an Empiric Selection

This debate will contrast broad use of immunotherapy with molecular profiling-guided individualized approaches in frontline care for metastatic endometrial cancer. Evaluate...

  • Moderator
    • Kathleen Moore, MD, MS
  • Presenter
    • John Diaz, MD
    • Brian Slomovitz, MD
Gynecological Cancers

Immunotherapy for All

This debate will contrast broad use of immunotherapy with molecular profiling-guided individualized approaches in frontline care for metastatic endometrial cancer. Evaluate clinical trial data supporting immunotherapy across patient populations alongside evidence for tailoring therapy based on molecular subtypes, reviewing practical considerations in applying these strategies in routine practice. Speakers will illuminate how evolving data are reshaping personalized care in endometrial cancer care.

Faculty will review key clinical trial data supporting immune-based regimens, including outcomes across molecular and histologic subtypes, and address patient selection, toxicity management, and integration of immunotherapy into current treatment algorithms. Participants will explore the expanding role of immunotherapy in improving outcomes for patients.

Presenter

Sunday, March 15 2:10–2:30 PM
Room Royal Ballroom 1
Gynecological Cancers

John Diaz

MD
Chief of Gynecologic Oncology
Miami Cancer Institute

John P. Diaz, M.D., FACOG, FACS, is a board-certified gynecologic oncologist with a distinguished career in clinical care, academic leadership and research. He currently serves as chair of the Department of Obstetrics and Gynecology at Florida International University Herbert Wertheim College of Medicine and holds multiple leadership roles at Baptist Health South Florida, including chief of gynecologic oncology, director of robotic surgery and director of clinical research in gynecologic oncology.
Dr. Diaz earned his medical degree from the University of Miami Miller School of Medicine, where he was inducted into Iron Arrow, the university’s highest honor society. He completed his residency in obstetrics and gynecology at Jackson Memorial Hospital/University of Miami and went on to complete his fellowship in gynecologic oncology at Memorial Sloan Kettering Cancer Center in New York, where he received the Department of Surgery Chairman’s Award for Excellence in Clinical Research.
A surgical innovator, Dr. Diaz has helped pioneer novel procedures such as fertility-sparing radical trachelectomy for early-stage cervical cancer and sentinel lymph node mapping in gynecologic malignancies. He also performed Florida’s first uterine transposition procedure for a patient with gynecologic cancer, preserving reproductive potential in a groundbreaking approach. In addition, he was awarded a $1.7 million research grant to investigate novel therapeutics for the treatment of gynecologic cancers.
Dr. Diaz has authored numerous peer-reviewed publications, remains deeply committed to medical education and mentorship. His work reflects an enduring dedication to advancing women’s cancer care, surgical innovation and academic leadership on both a regional and national level.

Molecular Profiling to Individualize Therapy – Immunotherapy Should Not Be an Empiric Selection

This debate will contrast broad use of immunotherapy with molecular profiling-guided individualized approaches in frontline care for metastatic endometrial cancer. Evaluate clinical trial data supporting immunotherapy across patient populations alongside evidence for tailoring therapy based on molecular subtypes, reviewing practical considerations in applying these strategies in routine practice. Speakers will illuminate how evolving data are reshaping personalized care in endometrial cancer care.

This discussion will review key molecular subtypes and biomarkers that inform treatment selection, including implications for immunotherapy, targeted agents, and combination strategies. Explore practical challenges in testing, interpretation, and implementation in routine practice for endometrial cancer therapy, and gain insight into how precision medicine approaches can optimize outcomes in this population.

Presenter

Sunday, March 15 2:30–2:50 PM
Room Royal Ballroom 1
Gynecological Cancers

Brian Slomovitz

MD
Director, Gynecologic Oncology
Mount Sinai Medical Center

A specialist in clinical trial development, endometrial cancer, low grade serous ovarian cancer, robotic surgery, sentinel lymph node evaluation, and immunotherapy, Dr. Brian Slomovitz is Director of Gynecologic Oncologic and Co-Chair of the Cancer Research Committee at Mount Sinai Medical Center in Miami Beach, Florida. He is also a Professor of Obstetrics and Gynecology at Florida International University.

Dr. Slomovitz is a member of the Board of Directors at the GOG Foundation and the Uterine Cancer Lead for GOG Partners. He is also the national or global principal investigator on a number of GOG Partners, NCI, and Alliance Foundation clinical trials. He authored more than 100 peer-reviewed articles and lectured extensively. In addition, Dr. Slomovitz has been recognized as a Top Doctor by Castle Connolly Medical for the past several years.

Dr. Slomovitz graduated from Rutgers University – New Jersey Medical School, and completed his residency at New York Presbyterian – Cornell Medical Center in 2002. At MD Anderson Cancer Center, he completed a fellowship in gynecologic oncology in 2006. He is board certified in both obstetrics and gynecology and gynecologic oncology.
General Session

Treatment of Platinum-Sensitive and Resistant Recurrent Ovarian Cancer: Optimizing Outcomes with Currently Available Therapies – The Regulatory Standard Is the Treatment Standard vs Rethinking Recurrent Ovarian Cancer – ADCs, New Taxane Combinations,

Explore treatment strategies for platinum-sensitive and platinum-resistant recurrent ovarian cancer, comparing optimization of outcomes with currently available therapies versus...

  • Moderator
    • Kathleen Moore, MD, MS
  • Presenter
    • Linda Duska, MD, MPH
    • Rebecca Porter, MD, PhD
Gynecological Cancers

Optimizing Outcomes with Currently Available Therapies – The Regulatory Standard Is the Treatment Standard

Explore treatment strategies for platinum-sensitive and platinum-resistant recurrent ovarian cancer, comparing optimization of outcomes with currently available therapies versus incorporation of emerging agents. Faculty will review clinical trial data, response patterns, and toxicity considerations across these approaches, providing expert perspectives on integrating established and emerging therapies to improve outcomes in recurrent ovarian cancer.

This session will focus on optimizing outcomes for patients with platinum-sensitive and platinum-resistant recurrent ovarian cancer using currently available therapies, and will review evidence supporting established chemotherapy regimens, targeted agents, and maintenance strategies across disease settings. Discussion will address sequencing, toxicity management, and tailoring treatment based on platinum sensitivity and prior therapy.

Presenter

Sunday, March 15 2:55–3:15 PM
Room Royal Ballroom 1
Gynecological Cancers

Linda Duska

MD, MPH
Professor, Obstetrics and Gynecology
University of Virginia School of Medicine

Dr. Linda Duska MD MPH is a Professor of Obstetrics and Gynecology, Division of Gynecologic Oncology at the University of Virginia School of Medicine in Charlottesville Virginia. She provides clinical care for women with gynecologic cancer includig surgery and chemotherapy, as well as for women with complex gynecologic surgical problems. Dr. Duska has been in practice since 1998, when she completed her Gynecologic Oncology Fellowship at the Massachusetts General Hospital in Boston, and moved to UVA in 2008 to assume the role of Gynecologic Oncology Fellowship Director. Currently, she manages the Gynecologic Oncology clinical reserach program, which includes a broad portfolio of clinical trials, including investigator initiated studies, NCI sponsored trials (NRG, ECTCN, SWOG, etc), GOG Foundation studies, and others. Dr. Duska has 4 grown children, and lives in Charlottesville with her husband and two dogs.

Rethinking Recurrent Ovarian Cancer – ADCs, New Taxane Combinations, Bispecifics – What Will the Future of Treatment Selection Look Like?

Explore treatment strategies for platinum-sensitive and platinum-resistant recurrent ovarian cancer, comparing optimization of outcomes with currently available therapies versus incorporation of emerging agents. Faculty will review clinical trial data, response patterns, and toxicity considerations across these approaches, providing expert perspectives on integrating established and emerging therapies to improve outcomes in recurrent ovarian cancer.

This session will examine emerging treatment strategies for platinum-sensitive and platinum-resistant recurrent ovarian cancer, with a focus on antibody-drug conjugates (ADCs), novel taxane combinations, and bispecific therapies. Faculty will review early-phase and evolving clinical data supporting these agents and their mechanisms of action, as well as how these therapies may be integrated into existing treatment paradigms. Learners will gain perspective on the potential of innovative agents to expand therapeutic options in recurrent ovarian cancer.

Presenter

Sunday, March 15 3:15–3:35 PM
Room Royal Ballroom 1
Gynecological Cancers
Faculty

Rebecca Porter

MD, PhD
Assistant Professor
Dana-Farber Cancer Institute

Dr. Rebecca Porter, MD, PhD is a Medical Oncologist in the Division of Gynecologic Oncology at Dana Farber Cancer Institute and an Assistant Professor of Medicine at Harvard Medical School. She also serves as the Director of Immunotherapy Research for the Division of Gynecologic Oncology, and her clinical and research efforts are centered on developing and translating novel immunotherapy strategies, including adoptive cell therapies, to patients with gynecologic cancers as well as performing biomarker studies to identify mediators of response and resistance to therapy. Dr. Porter maintains an active clinical practice seeing patients with ovarian, endometrial, cervical, vaginal and vulvar cancers.
General Session

Recurrent Ovarian Cancer in the ADC Era: Mirvetuximab and Emerging ADCs Should Define Treatment Selection by Biomarker vs Platinum Sensitivity Still Rules: Sequencing, Not Target Expression, Should Drive Decisions

This session will examine treatment selection in recurrent ovarian cancer in the era of antibody-drug conjugates (ADCs). Faculty will compare biomarker-driven use of agents such as...

  • Moderator
    • Kathleen Moore, MD, MS
  • Presenter
    • Marina Frimer, MD
    • Rebecca Porter, MD, PhD
Gynecological Cancers

Mirvetuximab and Emerging ADCs Should Define Treatment Selection by Biomarker

This session will examine treatment selection in recurrent ovarian cancer in the era of antibody-drug conjugates (ADCs). Faculty will compare biomarker-driven use of agents such as mirvetuximab with traditional platinum-based sequencing strategies, reviewing clinical evidence, resistance patterns, and practical considerations. Participants will gain insight into how emerging therapies may reshape decision-making.

This discussion will focus on the growing role of ADCs, including mirvetuximab, as biomarker-selected therapies. Faculty will review clinical trial data supporting improved outcomes in target-expressing populations and discuss how biomarker testing can guide treatment selection, improve precision, and potentially shift sequencing paradigms.

Debate Speaker

Sunday, September 27 1:30–1:50 PM
Gynecological Cancers
Faculty

Rebecca Porter

MD, PhD
Assistant Professor
Dana-Farber Cancer Institute

Dr. Rebecca Porter, MD, PhD is a Medical Oncologist in the Division of Gynecologic Oncology at Dana Farber Cancer Institute and an Assistant Professor of Medicine at Harvard Medical School. She also serves as the Director of Immunotherapy Research for the Division of Gynecologic Oncology, and her clinical and research efforts are centered on developing and translating novel immunotherapy strategies, including adoptive cell therapies, to patients with gynecologic cancers as well as performing biomarker studies to identify mediators of response and resistance to therapy. Dr. Porter maintains an active clinical practice seeing patients with ovarian, endometrial, cervical, vaginal and vulvar cancers.

Platinum Sensitivity Still Rules: Sequencing, Not Target Expression, Should Drive Decisions

This session will examine treatment selection in recurrent ovarian cancer in the era of antibody-drug conjugates (ADCs). Faculty will compare biomarker-driven use of agents such as mirvetuximab with traditional platinum-based sequencing strategies, reviewing clinical evidence, resistance patterns, and practical considerations. Participants will gain insight into how emerging therapies may reshape decision-making.

This discussion will emphasize the continued importance of platinum sensitivity in guiding treatment sequencing. Faculty will review evidence supporting established platinum-based approaches and argue that clinical context and sequencing strategy remain more impactful than target expression alone, with attention to durability, toxicity, and real-world applicability.

Debate Speaker

Sunday, September 27 1:50–2:10 PM
Gynecological Cancers
Faculty

Marina Frimer

MD
Associate Chief, Research and Academic Development
Northwell Health

Dr. Marina Frimer, a distinguished Gynecologic Oncologist, is currently the Vice Chair of Research and Academic Development at Northwell Health’s Department of Obstetrics and Gynecology. At Northwell Cancer Institute, Dr. Frimer is spearheading the development of a robust clinical and translational research program. Dr. Frimer is also the Director of Clinical Cancer Research at the Northwell Queens Cancer Center. Her translational work focuses on rare uterine cancers and cancer genomics, with collaborations with Cold Spring Harbor Laboratory. Her innovative translational research involves developing pre-clinical endometrial cancer models, including the cultivation of organoids to explore high grade uterine cancers and therapeutic options. Dr. Frimer has authored multiple publications and secured several grants to support her research initiatives. Notable projects include examining the mechanisms behind endometrial cancer disparities in African American populations and creating multi-omics maps of the human endometrium across diverse ancestries. Additionally, she is dedicated to building trust in clinical trials, partnering with the Hispanic Counseling Center to engage underrepresented communities. Dr. Frimer maintains an active clinical practice seeing patients with all gynecologic malignancies.
General Session

First-Line Advanced/Recurrent Endometrial Cancer: Chemo-Immunotherapy Is the New Standard for All Comers vs pMMR/MSS Disease Demands a Different Strategy: Targeted Combinations and Molecular Subtyping Over Reflexive IO

This session will explore first-line treatment strategies for advanced or recurrent endometrial cancer, examining whether chemo-immunotherapy should be broadly applied or tailored...

  • Moderator
    • Kathleen Moore, MD, MS
  • Presenter
    • Bhavana Pothuri, MD
    • Oladapo Yeku, MD, PhD, FACP, FASCO
Gynecological Cancers

Chemo-Immunotherapy Is the New Standard for All Comers

This session will explore first-line treatment strategies for advanced or recurrent endometrial cancer, examining whether chemo-immunotherapy should be broadly applied or tailored based on molecular subtype. Faculty will review key clinical trial data, including outcomes by mismatch repair status, and discuss biomarker-driven decision-making, toxicity considerations, and real-world implementation. Participants will gain practical insight into optimizing treatment selection in a rapidly evolving landscape.

This discussion will support chemo-immunotherapy as a new standard across patient populations. Faculty will highlight pivotal trials demonstrating improved outcomes with the addition of immunotherapy to chemotherapy, regardless of mismatch repair status, and discuss durability of benefit, safety, and ease of implementation in routine practice.

Debate Speaker

Sunday, September 27 3:30–3:50 PM
Gynecological Cancers
Faculty

Oladapo Yeku

MD, PhD, FACP, FASCO
Associate Professor
Mass General Brigham Cancer Institute / Harvard Medical School

Dr. Oladapo Yeku is an Associate Professor of Medicine at Harvard Medical School and the Director of Translational Research for the Gynecologic Oncology Program at the Mass General Brigham Cancer Institute. He is an Associate Editor for Hematology and Oncology at NEJM Evidence. Dr. Yeku completed his Medical Oncology fellowship training at Memorial Sloan Kettering Cancer Center (MSKCC) and is an expert on immunotherapy for gynecologic cancers. Dr. Yeku is actively involved as a Principal Investigator in early-phase drug development, immunotherapy, and adoptive cellular therapy clinical trials. His translational laboratory studies the immunosuppressive tumor microenvironment in Gynecologic Cancers and develops immunotherapeutic approaches such as bispecific T-cell engagers and Chimeric Antigen Receptor (CAR) T-cells to overcome these obstacles.

pMMR/MSS Disease Demands a Different Strategy: Targeted Combinations and Molecular Subtyping Over Reflexive IO

This session will explore first-line treatment strategies for advanced or recurrent endometrial cancer, examining whether chemo-immunotherapy should be broadly applied or tailored based on molecular subtype. Faculty will review key clinical trial data, including outcomes by mismatch repair status, and discuss biomarker-driven decision-making, toxicity considerations, and real-world implementation. Participants will gain practical insight into optimizing treatment selection in a rapidly evolving landscape.

This discussion will argue for a more tailored approach in pMMR/MSS disease. Faculty will examine the comparatively modest benefit of immunotherapy in this subgroup and emphasize the role of targeted combinations and molecular subtyping to guide treatment. Practical considerations around patient selection, sequencing, and emerging data will be addressed.

Debate Speaker

Sunday, September 27 3:50–4:10 PM
Gynecological Cancers
Faculty

Bhavana Pothuri

MD
Attending Physician
NYU Langone Health

Dr. Bhavana Pothuri is a Professor in the Departments of Obstetrics and Gynecology and Medicine at the New York University (NYU) School of Medicine, Medical Director of Clinical Trials Office (CTO), Director of Gynecologic Oncology Clinical Trials, Director of Gynecologic Oncology Research, and Site Principal Investigator for the Perlmutter Cancer Center, NYU Langone Health. Her roles nationally include: Gynecologic Oncology (GOG) Foundation Director of Diversity and Health Equity for Clinical Trials, GOG Partners, Associate Clinical Trials Advisor (Ovary and Endometrial Cancer), Society of Gynecologic Oncology Board of Directors, SGO Co-Chair COVID-19 Task Force, and NY Obstetrical Society (NYOB) Executive Council, President.
Back to top